CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Denmark's Lundbeck posts higher Q3 profit, raises FY revenue and EBITDA guidance

By Reuters News


Overview

  • Denmark pharma firm's Q3 2026 revenue rose 7% CER, with all regions contributing

  • Q3 adjusted EPS rose 19% year-over-year

  • Company raised full-year 2026 revenue and adjusted EBITDA growth guidance


Outlook

  • Lundbeck raises 2026 revenue growth guidance to 11%-12% CER from 7%-9%

  • Company now expects 2026 adjusted EBITDA growth of 15%-19% CER, up from 8%-14%

  • Company says Vyepti approval in Japan expected to support growth in Asia


Result Drivers

  • VYEPTI AND REXULTI GROWTH - Co said Q3 revenue growth was driven by strong Vyepti sales and solid contributions from Rexulti

  • PARTNERSHIP MODEL TRANSITION - Ongoing shift to partnership model in 27 markets supported revenue growth, per co

  • MARGIN PRESSURE – Gross margin fell in Q3 and 9-months on smaller Vyepti provision reversals, partner commissions and adverse product and geographic mix


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

DKK 6.60 bln

Q3 Adjusted EPS

DKK 1.71

Q3 EPS

DKK 1.28

Q3 Adjusted EBITDA

DKK 2.26 bln

Q3 EBITDA

DKK 2.24 bln


Analyst Coverage

  • The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 6 three months ago


Reuters Recommended Reads

  • Nov 9 - Boehringer, Zealand's obesity drug did not raise heart risks in trial, data shows

  • Nov 7 - Trial failures of Novartis, Novo Nordisk heart drugs leave experts guessing

  • Nov 9 - US FDA orders new eye risk warnings for Ozempic, Zepbound


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.